Latest Breaking News On - Darrin beaupre - Page 1 : vimarsana.com

IDEAYA Biosciences, Inc Reports First Quarter 2024 Financial Results and Provides Business Update

ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30.

United statesNew south walesAnthony joshuaDarrin beaupreWerner helicaseYujiros hataAndres ruiz brisenoProgram in solid tumorsMerck sharp dohmeExchange commissionInternational business gmbUs food drug administrationBiosciences incMerck co incProgram in tumorsKinghorn cancer centre

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial.

Andres ruiz brisenoMichael whiteDarrin beaupreExchange commissionBiosciences incChief medical officerChief scientific officerInvestor relations

IDEAYA Biosciences (IDYA) Selects Move-Forward Phase 2 Expansion Dose for IDE397

IDEAYA Biosciences (IDYA) Selects Move-Forward Phase 2 Expansion Dose for IDE397
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Michael whiteDarrin beaupreIdeaya biosciences incChief medical officerChief scientific officer

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

Trial will evaluate IDE161, IDEAYA s investigational PARG inhibitor, in combination with KEYTRUDA® , Merck s anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cancer Potential.

United statesDarrin beaupreAndres ruiz brisenoYujiros hataUs food drug administration fastBiosciences incMerck co incExchange commissionMerck sharp dohmeChief medical officerChief executive officerDrug administration fast trackMerck sharpAnnual reportInvestor relations

IDEAYA Biosciences, Inc Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting.

New south walesUnited kingdomWerner helicaseTrodelvy sacituzumab govitecan hziyAnthony joshuaAndres ruiz brisenoYujiros hataDarrin beaupreExchange commissionDarovasertib program in tumorsProgram in solid tumorsEuropean society for medical oncology congressCancer research united kingdomGilead sciencesHead department of medical oncologyKinghorn cancer centre